the stocks for companies developing cancer therapies were moving in morning trading on friday as biotechs and researchers shared new clinical findings in advance of next week’s american society of clinical oncology annual meeting   arcellx inc’s aclx stock jumped 119 after an abstract provided updated data for its cartddbcma svb securities analysts said in a note on friday that they were pleased to see that the experimental therapy “continues to have a competitive efficacy signal in 24 evaluable relapsedrefractory patients”   iovance biotherapeutics inc’s iova stock tumbled 540 toward a fiveyear low the day after the company shared data from a latestage clinical trial for its melanoma therapy candidate the data demonstrated a 29 objective response rate in one cohort of patients however the stock tanked in afterhours trading on thursday mizuho americas analyst mara goldstein attributed the stock drop to the difference in median duration of response in different groups of patients “there is a disconnect between the results and the stock price reaction” she told investors on friday   mirati therapeutics inc’s mrtx stock slid 416 toward a fouryear low the day after the company said its experimental treatment reduced tumors in 43 of patients with advanced lung cancer this is better data than what has been reported for amgen inc’s amgn lumakras which was approved in the us a year ago stifel analyst benjamin burnett said he thought the stock was down on lowerthanexpected median duration of response compared with lumakras’ median duration of response “in our view mrtx is more likely to succeed here than amgn” he wrote in a note to investors “while the stock is off on a negative secondline update we recommend focusing on what we think is a more important frontline catalyst later in the year”   springworks therapeutics inc’s swtx stock plummeted 556 toward a record low after the company shared data on thursday from a phase 12 clinical trial evaluating nirogacestat in combination with a glaxosmithkline’s gsk blenrep in patients with multiple myeloma jp morgan analysts called the data a “clear winhome run” but noted that it’s too early to make conclusions about the cohort expansion data this could “potentially create an overhang on the program until the update later in the year” they wrote   zymeworks inc’s zyme stock rallied as much as 52 before reversing course to fall 12 the day after sharing data that a combination of zanidatamab with docetaxel a common chemotherapy generated a 905 objective response rate as a firstline treatment for advanced her2 breast cancer svb securities analyst andrew berens said the data puts the experimental combination in the same category as roche holding ag’s rog herceptin and perjeta with docetaxel “ultimately we think that firstline breast opportunity could represent a meaningful opportunity for zyme and we attribute 852 million in peak ww sales in the indication” he told investors on friday the spdr sp biotech etf xbi was down 396 for the year while the sp 500 spx has declined 1378